Novartis Gains Rights to Antibiotic with Acquisition of Protez
Novartis (Basel, Switzerland) will acquire Protez Pharmaceuticals (Malvern, PA) for up to $400 million in cash.
Novartis (Basel, Switzerland) will acquire Protez Pharmaceuticals (Malvern, PA) for up to $400 million in cash. After the acquisition, Protez will become a stand-alone subsidiary of Novartis, maintaining its operations in Malvern, Pennsylvania.
The agreement provides Novartis with Protez’s research expertise and product pipeline including the North American and European rights to its lead product candidate PZ-601, an injectable antibiotic in the class of agents known as carbapenems. In 2005, Protez entered an exclusive licensing agreement with its originator, Dainippon Sumitomo Pharma Co., Ltd. (DSP, Osaka, Japan), which has expertise in carbapenem research and development through meropenem, to develop and commercialize PZ-601 in North America and Europe. Since then, Protez, in collaboration with DSP, advanced the novel antibiotic to Phase 2 human clinical trials.
Antibiotics in the carbapenem class are useful in treating serious and often life-threatening infections caused by Gram-negative and Gram-positive bacteria. PZ-601 has been shown to have a broad spectrum of activity that could offer better coverage over existing injectable antibiotics, especially multidrug resistant bacteria, including MRSA.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
